Respiratory Syncytial Virus Bronchiolitis Has Different Subtypes
By LabMedica International staff writers Posted on 30 Jun 2021 |
Image: The Bioanalyzer RNA 6000 Nano assay provides reliable and reproducible characterization of total RNA and mRNA from multiple sample types, from as low as 5 ng of total RNA (Photo courtesy of Agilent)
Bronchiolitis is the leading cause of hospitalization in infants in the USA, accounting for about 110,000 hospitalizations annually. In addition to the substantial acute morbidity, around 30% of infants hospitalized for bronchiolitis (“severe bronchiolitis”) subsequently develop asthma in childhood.
Of the major causative pathogens, respiratory syncytial virus (RSV) infection during infancy has the largest population attributable fraction. While bronchiolitis has been considered a single disease with similar mechanisms, emerging evidence suggests heterogeneity in clinical presentations and chronic morbidities (e.g., subsequent risk of recurrent wheeze and asthma).
Medical Scientists at the Massachusetts General Hospital (Boston, MA, USA) and their colleagues analyzed the data from a multicenter prospective cohort study of infants hospitalized for bronchiolitis. This prospective cohort study completed enrollment of 1,016 infants (age < 1 year) hospitalized with bronchiolitis at 17 sites across 14 USA states. Of these 1,016 infants (median age, 3 months; female, 40%), 921 (91%) completed the run-in procedure.
The team isolated total RNA from the nasopharyngeal samples using Trizol LS reagent (ThermoFisher Scientific, Waltham, MA, USA) in combination with the Direct-zol RNA Miniprep Kit (Zymo Research, Irvine, CA, USA). RNA quantity was measured with the (ThermoFisher Scientific Qubit 2.0 fluorometer and its quality was assessed with the Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA) using the RNA 6000 Nano kit.
To provide further insights, the team analyzed diverse clinical, genetic, and molecular data from 221 infants hospitalized with RSV bronchiolitis who were followed until age 5 years. They gathered information on the viruses that had infected the children, as well as information on the microbes, metabolites, and immune response-related molecules present in the children’s nasal passages.
The scientists reported that based on their analyses, four biologically and clinically meaningful subtypes, or endotypes, of RSV bronchiolitis exist. Of these, 1 endotype, which is characterized by coinfection by rhinovirus, dominance by specific bacteria, and high interferon (IFN) response, had an approximate 40% risk of developing asthma by age five.
The investigators identified four biologically- and clinically-meaningful endotypes: “(1) clinicalclassicmicrobiomeM nonliquefaciensinflammationIFN-intermediate; (2) clinicalatopicmicrobiomeS pneumoniae/M catarrhalisinflammationIFN-high; (3) clinicalseveremicrobiomemixedinflammationIFN-low; and (4) clinicalnon-atopicmicrobiomeM.catarrhalisinflammationIL-6. Particularly, compared with endotype A infants, endotype B infants, had a significantly higher risk for developing asthma (9% versus 38%).
Yoshihiko Raita, MD, an Emergency Medicine physician and first author of the study, said, “Our data add significant support to the emerging concept that bronchiolitis represents several diseases with unique biological mechanisms. For clinicians, our findings give an evidence base for the early identification of high-risk children during an important period of airway development, early infancy.
The authors concluded that by applying an integrated omics approach to data from a multicenter prospective cohort study of 221 infants with RSV bronchiolitis, they had identified four biologically distinct and clinically meaningful endotypes. The study was published on June 14, 2021, in the journal Nature Communications.
Related Links:
Massachusetts General Hospital
ThermoFisher Scientific
Zymo Research
Agilent
Of the major causative pathogens, respiratory syncytial virus (RSV) infection during infancy has the largest population attributable fraction. While bronchiolitis has been considered a single disease with similar mechanisms, emerging evidence suggests heterogeneity in clinical presentations and chronic morbidities (e.g., subsequent risk of recurrent wheeze and asthma).
Medical Scientists at the Massachusetts General Hospital (Boston, MA, USA) and their colleagues analyzed the data from a multicenter prospective cohort study of infants hospitalized for bronchiolitis. This prospective cohort study completed enrollment of 1,016 infants (age < 1 year) hospitalized with bronchiolitis at 17 sites across 14 USA states. Of these 1,016 infants (median age, 3 months; female, 40%), 921 (91%) completed the run-in procedure.
The team isolated total RNA from the nasopharyngeal samples using Trizol LS reagent (ThermoFisher Scientific, Waltham, MA, USA) in combination with the Direct-zol RNA Miniprep Kit (Zymo Research, Irvine, CA, USA). RNA quantity was measured with the (ThermoFisher Scientific Qubit 2.0 fluorometer and its quality was assessed with the Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA) using the RNA 6000 Nano kit.
To provide further insights, the team analyzed diverse clinical, genetic, and molecular data from 221 infants hospitalized with RSV bronchiolitis who were followed until age 5 years. They gathered information on the viruses that had infected the children, as well as information on the microbes, metabolites, and immune response-related molecules present in the children’s nasal passages.
The scientists reported that based on their analyses, four biologically and clinically meaningful subtypes, or endotypes, of RSV bronchiolitis exist. Of these, 1 endotype, which is characterized by coinfection by rhinovirus, dominance by specific bacteria, and high interferon (IFN) response, had an approximate 40% risk of developing asthma by age five.
The investigators identified four biologically- and clinically-meaningful endotypes: “(1) clinicalclassicmicrobiomeM nonliquefaciensinflammationIFN-intermediate; (2) clinicalatopicmicrobiomeS pneumoniae/M catarrhalisinflammationIFN-high; (3) clinicalseveremicrobiomemixedinflammationIFN-low; and (4) clinicalnon-atopicmicrobiomeM.catarrhalisinflammationIL-6. Particularly, compared with endotype A infants, endotype B infants, had a significantly higher risk for developing asthma (9% versus 38%).
Yoshihiko Raita, MD, an Emergency Medicine physician and first author of the study, said, “Our data add significant support to the emerging concept that bronchiolitis represents several diseases with unique biological mechanisms. For clinicians, our findings give an evidence base for the early identification of high-risk children during an important period of airway development, early infancy.
The authors concluded that by applying an integrated omics approach to data from a multicenter prospective cohort study of 221 infants with RSV bronchiolitis, they had identified four biologically distinct and clinically meaningful endotypes. The study was published on June 14, 2021, in the journal Nature Communications.
Related Links:
Massachusetts General Hospital
ThermoFisher Scientific
Zymo Research
Agilent
Latest Microbiology News
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA